An open label, randomized clinical comparability study of the current liquid and commercial liquid formulations

Trial Profile

An open label, randomized clinical comparability study of the current liquid and commercial liquid formulations

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
    • 21 Jan 2008 Status changed from recruiting to in progress.
    • 23 Oct 2007 Status changed from in progress to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top